Cargando…

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting

Detalles Bibliográficos
Autores principales:	Spearman, P, Tomaras, G, Montefiori, D, Huang, Y, Ahmed, H, Elizaga, M, Hural, J, McElrath, J, Ouedraogo, L, Pensiero, M, Butler, C, Kalams, S, Overton, ET, Barnett, S, Group, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441648/ http://dx.doi.org/10.1186/1742-4690-9-S2-P137

Ejemplares similares

Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses
por: Curran, Rhonda M., et al.
Publicado: (2009)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Immunogenicity of the outer domain of a HIV-1 clade C gp120
por: Chen, Hongying, et al.
Publicado: (2007)

Antigen processing sites in gp120 are conserved across HIV virus clades
por: Yu, B, et al.
Publicado: (2012)

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate
por: Visciano, Maria Luisa, et al.
Publicado: (2013)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses
por: Mouquet, Hugo, et al.
Publicado: (2011)

P19-42. Engineering, expression and antigenic and immunogenic characterization of novel soluble clade A/B heterotrimeric gp140-envelope glycoproteins
por: Sellhon, G, et al.
Publicado: (2009)

Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector
Publicado: (2020)

Rate and affinity binding constants determined by SPR spectroscopy reveal differential antigenicity of HIV gp120 and gp140
por: Gearhart, TL, et al.
Publicado: (2012)

P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140
por: Donnelly, L, et al.
Publicado: (2009)

P11-12. A novel vaginal ring device for the sustained delivery of recombinant C-clade HIV-1 CN54gp140
por: Morrow, RJ, et al.
Publicado: (2009)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities
por: Seaton, Kelly E., et al.
Publicado: (2014)

Focusing the immune response on the V3 loop of HIV-1 gp120 induces cross-clade neutralizing
por: Zolla-Pazner, Susan, et al.
Publicado: (2006)

Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120
por: Chen, Hongying, et al.
Publicado: (2008)

Antibody responses after intravaginal immunisation with trimeric HIV-1(CN54) clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation
por: Cranage, Martin P., et al.
Publicado: (2011)

HIV-1 Gp120 clade B/C induces a GRP78 driven cytoprotective mechanism in astrocytoma
por: López, Sheila N., et al.
Publicado: (2017)

Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms
por: Donnelly, Louise, et al.
Publicado: (2011)

V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques
por: Styles, Tiffany M., et al.
Publicado: (2022)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants
por: Churchyard, Gavin, et al.
Publicado: (2016)

Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL
por: Isik, Gözde, et al.
Publicado: (2014)

Glycosylation and Disulfide Bond Analysis of Transiently and Stably Expressed Clade C HIV-1 gp140 Trimers in 293T Cells Identifies Disulfide Heterogeneity Present in Both Proteins and Differences in O-Linked Glycosylation
por: Go, Eden P., et al.
Publicado: (2014)

The role of intermolecular disulfide bonding in deposition of GP140 in the extracellular matrix
Publicado: (1984)

Characterization and Immunogenicity of HIV Envelope gp140 Zera(®) Tagged Antigens
por: Ximba, Phindile, et al.
Publicado: (2020)

Development of a Stable MGAT1(−) CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies
por: Doran, Rachel C., et al.
Publicado: (2018)

A Human Antibody to the CD4 Binding Site of gp120 Capable of Highly Potent but Sporadic Cross Clade Neutralization of Primary HIV-1
por: Gach, Johannes S., et al.
Publicado: (2013)

Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques
por: Zurawski, Gerard, et al.
Publicado: (2016)

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap
por: Gray, Glenda E., et al.
Publicado: (2016)

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
por: Rouphael, Nadine G., et al.
Publicado: (2019)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity
por: Diskin, Ron, et al.
Publicado: (2010)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
por: Borst, Andrew J, et al.
Publicado: (2018)

One-step sequence and structure-guided optimization of HIV-1 envelope gp140
por: Malladi, Sameer Kumar, et al.
Publicado: (2020)

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice
por: Buffa, Viviana, et al.
Publicado: (2012)

Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
por: Ventura, John D., et al.
Publicado: (2022)

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
por: Shen, Xiaoying, et al.
Publicado: (2020)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis
por: Duchemin, Maxence, et al.
Publicado: (2018)

CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization
por: Katinger, D, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_geltjb0iqfrdq6baafrv35cgo2